Search

NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. has issued the following news release: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage [...]

ENPNewswire-August 11, 2020--Biohaven Reports Second Quarter 2020 Financial Results and Recent Business Developments (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 10082020 - NEW HAVEN - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: [...]

Boston, Massachusetts: Mintz has issued the following press release: Mintz served as legal counsel to global investment firm Sixth Street in its $500 million structured term loan financing facility to [...]

- NURTEC(TM) ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share - Company well-capitalized with recent non-dilutive [...]

ENPNewswire-August 10, 2020--ROYALTY PHARMA AND BIOHAVEN ANNOUNCE FUNDING AGREEMENT TOTALING UP TO $450 MILLION (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 07082020 - NEW YORK - Royalty Pharma (Nasdaq: RPRX) and [...]

ENPNewswire-August 10, 2020--Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 07082020 - NEW HAVEN - Biohaven Pharmaceutical Holding Company Ltd. [...]

ENPNewswire-August 10, 2020--BIOHAVEN ANNOUNCES UP TO $500 MILLION NON-DILUTIVE TERM LOAN WITH SIXTH STREET (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 07082020 - NEW HAVEN - Biohaven Pharmaceutical Holding Company Ltd. [...]

(GlobeNewswire) - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the companys [...]

- Strategic, Non-Dilutive, Growth Capital Supports Commercialization of NURTEC(TM) ODT and Company's Pipeline Development NEW HAVEN, Conn., Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ('Biohaven' [...]

- Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a [...]

Sharol Klise never thought of herself as a storyteller, but in June she became one, working with the well-known storytelling group The Moth and Biohaven Pharmaceuticals in a live event [...]

Byline: Rob Lenihan To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: https://www.thestreet.com/investing/biohaven-teams-with-khloe-kardashian-to-promote-migraine-drug Biohaven Pharmaceutical Co. (BHVN) teamed with the reality-TV star Khloe [...]

NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. has issued the following news release: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that it presented data from 25 accepted abstracts [...]

ENPNewswire-June 17, 2020--BIOHAVEN PRESENTS NURTEC CLINICAL AND PHARMACOECONOMIC DATA AT THE AMERICAN HEADACHE SOCIETY VIRTUAL ANNUAL SCIENTIFIC MEETING (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 16062020 - NEW HAVEN - Biohaven [...]

- Key presentations, including new analyses, highlight NURTEC clinical benefits including rapid and sustained efficacy with a single dose, low rescue medication use, long-term safety in patients with cardiovascular risk [...]

ENPNewswire-June 11, 2020--Biohaven Appoints Bob Hugin to its Board of Directors (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 10062020 - NEW HAVEN, Conn. - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), [...]

- Former Chief Executive Officer and Executive Chairman of Celgene Corporation brings deep leadership experience to Biohaven Board NEW HAVEN, Conn., June 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company [...]

Washington: Biohaven Pharmaceutical Holding Company Ltd., has filed FORM 8K (Current Report) with Securities and Exchange Commission on May 19, 2020: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 [...]

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability, and pharmacoeconomic value of NURTEC (rimegepant) on [...]

NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. has issued the following news release: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that it will present data from 25 accepted [...]

ENPNewswire-May 19, 2020--BIOHAVEN SHOWCASES CLINICAL AND PHARMACOECONOMIC DATA FOR NURTEC ODT WITH 25 PRESENTATIONS ON THE 2020 AMERICAN ACADEMY OF NEUROLOGY SCIENCE HIGHLIGHTS VIRTUAL PLATFORM (C)2020 ENPublishing - http://www.enpublishing.co.uk Release [...]

- Data spotlights NURTEC as the first and only CGRP-targeting agent using a quick-dissolve ODT technology for fast onset of action, return to normal function within one hour and sustained [...]

NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. has issued the following press release: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the 'Company'), a commercial-stage biopharmaceutical company with a portfolio of [...]

- Migraine has been an unwelcome part of Jennifer (Jennie) Latson's life for more than 25 years. On average, she has 10-12 migraine attacks per month. They can cause her [...]

Biohaven Pharmaceutical Holding Company Ltd. ('Biohaven') and Genpharm Services, a leading partner for innovative pharmaceuticals in Dubai, announced today an agreement to distribute NURTEC ODT (rimegepant) in the Middle East [...]

- Migraine has been an unwelcome part of Jennifer (Jennie) Latson's life for more than 25 years. On average, she has 10-12 migraine attacks per month. They can cause her [...]

NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. has issued the following news release: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ('Biohaven') and Genpharm Services, a leading partner for innovative pharmaceuticals [...]

- Biohaven and Genpharm's agreement will bring NURTEC(TM) ODT, the first oral, quick-dissolve, calcitonin gene related peptide (CGRP) antagonist to patients in the Middle East and the Gulf Region - [...]

2020 DEC 1 (NewsRx) -- By a News Reporter-Staff News Editor at Managed Care Business Week -- Up to 55% of migraine patients do not have sufficient relief with currently [...]

M2 PHARMA-October 15, 2020-US FDA Accepts Biohaven's Supplemental New Drug Application of Nurtec ODT for the Preventive Treatment of Migraine (C)2020 M2 COMMUNICATIONS - The US Food and Drug Administration [...]